Akero Therapeutics, Inc. Common Stock (AKRO)
Akero Therapeutics, Inc. is a biotechnology company focused on developing transformative therapies for chronic metabolic diseases, including non-alcoholic steatohepatitis (NASH). Founded to leverage its expertise in liver biology and medicinal chemistry, Akero aims to address areas with significant unmet medical needs through innovative drug candidates targeting liver fat accumulation and inflammation.
Company News
Akero Therapeutics will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, discussing their clinical-stage development of treatments for metabolic diseases, with a focus on their lead product candidate efruxifermin (EFX).
Akero Therapeutics, a biotech company developing a potential treatment for a liver disease, saw its stock soar 97% after positive midstage clinical trial results. The article discusses the company's pipeline, the unmet need in this area, and the potential for accelerated approval, while also noting the risks involved as Akero's only pipeline candidate.
Akero Therapeutics' CFO, William Richard White, sold over $976,000 worth of company stock, while also acquiring nearly $209,000 worth of shares through option exercises. The transactions were carried out under a pre-established trading plan.
Viking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its experimental NASH drug. However, shares drop as management did not provide any info on future plans.
Madrigal Pharmaceuticals on Thursday received the FDA’s first approval of a drug designed to treat a severe liver disease known as MASH.